Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma

NCT06088290 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT06088290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06088290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Controlled, Open-label, Phase III Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Patients With Metastatic Leiomyosarcoma
Lead sponsor
PharmaMar
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 21, 2023
Completion date
August 30, 2029
Enrollment
469 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma